Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

More than 3 years after construction commenced, IDRM is proud to announce that the IMS-Tetsuya Nakamura Building, which houses the new Institute, at Old Road Campus has been completed.

Despite the challenges presented by BREXIT and the COVID-19 pandemic the building has now seen its practical completion and been officially handed over to Oxford University.

IDRM research groups are eager to get started in their common goal to treat some of the world’s most prolific diseases. Over the next few years, the IDRM will house around 240 world-leading scientists who will foster multidisciplinary collaborations at the intersection of developmental biology and regenerative medicine.

Professor Paul Riley, British Heart Foundation Professor of Regenerative Medicine and Director of the IDRM said:

“Completion of the IMS-Tetsuya Nakamura Building to house the Institute of Developmental & Regenerative Medicine is a landmark moment. It marks 10 years of fundraising, planning and construction; having been born as an initial concept from a conversation between myself and my close colleague Professor Georg Hollander in the senior common room of Jesus College."  

"We are truly indebted to Dr Tetsuya Nakamura and the British Heart Foundation for their very generous support of the building and to the many colleagues here in Oxford who have contributed to the project as well as the architects SRA, project managers RIDGE, main contractor McLaughlin & Harvey and numerous other consultants and engineers. The research space is state-of-the art and we are blessed with cutting edge platforms, including advanced imaging as part of the Oxford-Zeiss Centre of Excellence.” 

“We now look forward to the next very exciting phase of filling the Institute with world leading researchers and working collaboratively across the fields of neuroscience, cardiovascular and immunology to pioneer new treatments for birth defects and acquired diseases”.

 

Read full story on the IDRM website